:: Volume 3, Issue 2 (Int J Mol Cell Med 2014) ::
Int J Mol Cell Med 2014, 3(2): 95-101 Back to browse issues page
UBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia
Atefeh Seghatoleslam 1, Farzaneh Bozorg-Ghalati2 , Ahmad Monabati3 , Mohsen Nikseresht4 , Ali Akbar Owji2
1- Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. , seghatolea@sums.ac.ir
2- Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
3- Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4- Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Abstract:   (27718 Views)
Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1 as a new characterized gene of E2 enzyme family is located on chromosome 1 and reported to be altered in some malignancies. In this study, we aimed to explore the expression pattern of UBE2Q1 gene in children with ALL. For this purpose, a series of RT - PCR and quantitative RT - PCR were performed on a collection of 20 bone marrow samples of ALL patients and the same number of whole blood samples of age - matched normal subjects. Gel electrophoresis of RT - PCR products revealed the expression of UBE2Q1 mRNA in most of the normal (90%) and about half of the leukemic (45%) samples. QRT - PCR data indicated that only 1 patient out of 20 (5%) showed up regulation of the gene (> 2 folds). In 4 patients (20%), the expression of UBE2Q1 mRNA was equivocal (from 1/2 to 2) and in 15 cases (75%), the gene was down regulated (> 1/2) when compared to the normal samples. In conclusion, down regulation of UBE2Q1 in the majority of the leukemic samples suggests its potential implication in the pathogenesis of ALL. UBE2Q1 can be considered as a molecular marker and a candidate targeting to treat ALL in the future.
Keywords: Ubiquitin-conjugating enzyme, UBE2Q1, QRT-PCR, pediatric acute lymphoblastic leukemia
Full-Text [PDF 155 kb]   (3460 Downloads)    
Type of Study: Original Article | Subject: Cancer
Received: 2013/12/23 | Accepted: 2014/02/1 | Published: 2014/02/19


XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 3, Issue 2 (Int J Mol Cell Med 2014) Back to browse issues page